<link rel="stylesheet" href="/res/styles.39be4579664c3a48.css">
Artículo

Pharmacotherapies for Parkinson’s disease symptoms related to cholinergic degeneration

Pérez Lloret, Santiago Icon; Peralta, Cecilia Mariana Icon; Barrantes, Francisco Jose Icon

Otros responsables

Fecha

10/2016

Editorial

Informa Healthcare

Revista

Expert Opinion on Pharmacotherapy

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

1465-6566

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Resumen

Introduction: Dopamine depletion is one of the most important features of Parkinson’s Disease (PD). However, insufficient response to dopaminergic replacement therapy suggests the involvement of other neurotransmitter systems in the pathophysiology of PD. Cholinergic degeneration contributes to gait impairments, cognitive impairment, psychosis, and REM-sleep disturbances, among other symptoms. Areas covered: In this review, we explore the idea that enhancing cholinergic tone by pharmacological or neurosurgical procedures could be a first-line therapeutic strategy for the treatment of symptoms derived from cholinergic degeneration in PD. Expert opinion: Rivastigmine, a drug that increases cholinergic tone by inhibiting the enzyme cholinesterase, is effective for dementia, whereas the use of Donepezil is still in the realm of investigation. Interesting results suggest the efficacy of these drugs in the treatment of gait dysfunction. Evidence on the clinical effects of these drugs for psychosis and REM-sleep disturbances is still weak. Stimulation of the pedunculo-pontine tegmental nuclei (which provide cholinergic innervation to the brain stem and subcortical nuclei) has also been used with some success for the treatment of gait dysfunction. Anticholinergic drugs should be used with caution in PD, as they may aggravate cholinergic symptoms. Notwithstanding, in some patients they might help control parkinsonian motor symptoms.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa